Filter
Reset all

Subjects

Content Types

Countries

API

Certificates

Data access

Data access restrictions

Database access

Database access restrictions

Data licenses

Data upload

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 9 result(s)
Country
Human biomaterial banks (short: biobanks) are collections of human body substances (i.e. blood, DNA, urine or tissue) connected with disease specific information. This allow for research of relations between deseases and underlying (molecular) modifications and paves the way for developing target-oriented therapies ("personalized medicine"). The biobank material arises from samples taken for therapeutical or diagnostic reasons or is extracted in the context of clinical trials. An approval for usage by the patient is always needed prior to any research activities.
The data in the U of M’s Clinical Data Repository comes from the electronic health records (EHRs) of more than 2 million patients seen at 8 hospitals and more than 40 clinics. For each patient, data is available regarding the patient's demographics (age, gender, language, etc.), medical history, problem list, allergies, immunizations, outpatient vitals, diagnoses, procedures, medications, lab tests, visit locations, providers, provider specialties, and more.
Country
Since 2004, the Leibniz Institute for Prevention Research and Epidemiology – BIPS has been working on the establishment and maintenance of the project-based German Pharmacoepidemiological Research Database (short GePaRD). GePaRD is based on claims data from statutory health insurance (SHI) providers and currently includes information on about 20 million persons who have been insured with one of the participating providers since 2004. Per data year, there is information on approximately 17% of the general population from all geographical regions of Germany.
The database aims to bridge the gap between agent repositories and studies documenting the effect of antimicrobial combination therapies. Most notably, our primary aim is to compile data on the combination of antimicrobial agents, namely natural products such as AMP. To meet this purpose, we have developed a data curation workflow that combines text mining, manual expert curation and graph analysis and supports the reconstruction of AMP-Drug combinations.
Country
The National Science and Technology Resource Sharing Service Platform belongs to the national science and technology innovation base of basic support and condition guarantee. Facing the needs of scientific and technological innovation, economic and social development, innovative social governance, and building a safe China, it strengthens the effective integration of high-quality scientific and technological resources and improves the efficiency of scientific and technological resources. Scientific research, technological progress and social development provide networked and socialized scientific and technological resource sharing services.
Content type(s)
CaPSURE™ is a longitudinal, observational study of approximately 15,000 men with all stages of biopsy-proven prostate cancer. Patients have enrolled at 43 community urology practices, academic medical centers, and VA hospitals throughout the United States since 1995. CEASAR stands for Comparative Effectiveness Analysis of Surgery and Radiation. The ongoing goal of CEASAR is to help learn more about what prostate cancer treatments work best, for which patients, in whose hands. There are currently about 3,600 men with a prostate cancer diagnosis participating in CEASAR. Three rounds of surveys have been completed, with the first carried out in the spring of 2010. We are currently in the process of conducting our fourth survey with the same group of men in our study. This survey, our Three Year Follow-up, will occur throughout the summer of 2014.
Country
The Canadian Longitudinal Study on Aging (CLSA) is a large, national, long-term study of more than 50,000 individuals who were between the ages of 45 and 85 when recruited. These participants will be followed until 2033 or death. The aim of the CLSA is to find ways to help us live long and live well, and understand why some people age in healthy fashion while others do not.
The Whitehall II study was established to explore the relationship between socio-economic status, stress and cardiovascular disease. A cohort of 10,308 participants aged 35-55, of whom 3,413 were women and 6,895 men, was recruited from the British Civil Service in 1985. Since this first wave of data collection, self-completion questionnaires and clinical data have been collected from the cohort every two to five years with a high level of participation. Data collection is intended to continue until 2030.